Form 4: Core Laboratories Director Acquires Shares

Core Laboratories Director Harvey Robert Klingensmith reported the acquisition of 8,069 shares of common stock.

Summary

• Harvey Robert Klingensmith, a Director at Core Laboratories Inc., acquired 8,069 shares of common stock on April 1, 2026.
• The acquisition was made at a price of $0, indicating it was likely a grant or award.
• Following this transaction, Klingensmith beneficially owns 50,031 shares of common stock.
• Additionally, 7,895 restricted shares were acquired on April 1, 2026, which are subject to a one-year vesting period ending April 1, 2027.
• These restricted shares will be distributed as common stock upon Klingensmith's separation from the Board, subject to deferral elections.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on routine equity awards and acquisitions by a director, without significant new financial information or strategic shifts.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• The acquisition of 8,069 shares at $0 suggests a form of compensation or incentive award.
• The vesting schedule for restricted shares indicates a commitment to long-term alignment with the company.

Risks

• The restricted shares are subject to a deferral election under Treasury Regulation 1.409A-2, which could impact the timing of distribution.
• Distribution of vested restricted shares is contingent upon the Reporting Person's separation of service from the Board.

Future Outlook

The filing does not contain forward-looking statements or guidance. The vesting of restricted shares is tied to future events such as separation from the Board.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. Director purchases, especially when at a zero cost basis, often represent equity awards intended to align management incentives with shareholder value over the long term.

Stakeholder Impact

• Shareholders: The acquisition by a director may be interpreted as a positive signal of confidence in the company's long-term prospects.
• Employees: The restricted stock award structure may serve as an incentive for key personnel.
• Management: The filing details compensation-related equity awards to a director.

Next Steps

• Distribution of vested restricted shares upon Reporting Person's separation of service from the Board.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Core Laboratories, CLB, Director, Stock Acquisition, Restricted Stock, Beneficial Ownership